Tesamorelin + CJC-1295 (No DAC) + Ipamorelin – 6mg / 3mg / 3mg (3ml Pen)

Tesamorelin + CJC-1295 No DAC + Ipamorelin 6mg/3mg/3mg – Triple Peptide Research Blend

Tesamorelin + CJC-1295 No DAC + Ipamorelin is a three-component research formulation containing two growth hormone-releasing hormone (GHRH) analogues and a synthetic growth hormone secretagogue.

The combination brings together compounds investigated for their effects on pituitary growth hormone secretion, endocrine regulation and receptor-mediated signalling.

Tesamorelin and CJC-1295 No DAC both act through the GHRH receptor, while Ipamorelin activates the growth hormone secretagogue receptor GHS-R1a, also known as the ghrelin receptor.

This distinction makes the formulation relevant to research examining overlapping and complementary growth hormone regulatory pathways.

The product contains 6mg Tesamorelin, 3mg CJC-1295 No DAC and 3mg Ipamorelin in a 3ml pen.

Understanding the Three-Peptide Formulation

Although the formulation contains three peptides, it primarily engages two receptor systems involved in growth hormone secretion.

Each compound has different structural and pharmacological characteristics.

Tesamorelin – GHRH Analogue

Tesamorelin is a modified 44-amino-acid analogue of human growth hormone-releasing hormone.

It activates GHRH receptors on pituitary somatotroph cells, stimulating intracellular signalling associated with growth hormone secretion.

Tesamorelin also has an established clinical research history involving visceral adipose tissue in adults with HIV-associated lipodystrophy.

These clinical findings relate to specific pharmaceutical formulations and cannot automatically be applied to investigational combinations.

CJC-1295 No DAC – Modified GHRH Signalling

CJC-1295 No DAC is a modified GHRH analogue investigated for its resistance to enzymatic degradation and its effects on pituitary hormone signalling.

Unlike the longer-acting DAC-containing variant, CJC-1295 No DAC lacks the drug-affinity complex modification responsible for prolonged albumin binding.

Both CJC-1295 No DAC and Tesamorelin activate the GHRH receptor.

Their presence in the same formulation therefore represents overlapping receptor activity rather than two independent growth hormone-releasing pathways.

Ipamorelin – Ghrelin Receptor Activation

Ipamorelin is a synthetic pentapeptide that activates GHS-R1a.

This receptor influences growth hormone secretion through signalling mechanisms distinct from those associated with GHRH receptors.

Ipamorelin has attracted research interest because preclinical studies demonstrated comparatively selective growth hormone responses, with less pronounced ACTH and cortisol stimulation than certain earlier growth hormone-releasing peptides.

These findings do not establish complete hormonal selectivity or clinical safety for the combined formulation.

Growth Hormone and Muscle Physiology Research

Growth hormone participates in several physiological processes associated with protein metabolism, tissue development and skeletal muscle regulation.

Research involving GHRH analogues and growth hormone secretagogues helps scientists investigate the upstream endocrine mechanisms controlling growth hormone secretion.

Relevant areas of investigation include:

• Pituitary growth hormone secretion: Understanding responses to GHRH and ghrelin receptor activation.
• Muscle physiology: Investigating endocrine signalling associated with protein metabolism and skeletal muscle tissue.
• IGF-1 regulation: Examining downstream pathways influenced by circulating growth hormone.
• Receptor pharmacology: Comparing overlapping GHRH receptor activity with complementary ghrelin receptor signalling.
• Metabolic regulation: Investigating pathways associated with lipid metabolism and energy balance.
• Hormonal selectivity: Studying growth hormone responses alongside other endocrine markers.

Although these pathways are relevant to muscle physiology, there is no established clinical evidence that this specific combination improves muscle growth, strength, recovery or athletic performance.

Researchers interested in related compounds can explore our collection of growth hormone and performance research peptides, featuring individual compounds and formulations investigated for endocrine signalling, muscle physiology and growth-related biological processes.

Mechanism of Action

GHRH Receptor and cAMP Signalling

Both Tesamorelin and CJC-1295 No DAC activate the growth hormone-releasing hormone receptor (GHRHR).

GHRHR activation engages Gs protein-mediated signalling and increases intracellular cyclic adenosine monophosphate (cAMP).

These processes contribute to growth hormone secretion from anterior pituitary somatotroph cells.

Because the two compounds interact with the same receptor system, their combined presence does not establish additive or synergistic activity.

Ghrelin Receptor Signalling

Ipamorelin activates the growth hormone secretagogue receptor GHS-R1a.

This receptor engages intracellular signalling mechanisms involving phospholipase C and calcium mobilisation.

The pathway differs from GHRH receptor signalling, providing a mechanistic basis for investigating interactions between growth hormone regulatory systems.

Complementary and Overlapping Pathways

Studies involving GHRH and various growth hormone secretagogues have demonstrated enhanced growth hormone secretion when both receptor pathways are activated under certain experimental conditions.

However, those findings do not establish that combining two GHRH analogues with Ipamorelin produces a greater response than simpler formulations.

The specific interactions between Tesamorelin, CJC-1295 No DAC and Ipamorelin require direct experimental investigation.

Somatostatin and Endocrine Regulation

Somatostatin inhibits pituitary growth hormone secretion.

The balance between stimulatory activity from GHRH and ghrelin receptor pathways and inhibitory somatostatin signalling contributes to the regulation of growth hormone release.

Research into these interacting mechanisms helps clarify the complexity of growth hormone secretion.

Scientific Research Applications

1. Multi-Component Receptor Pharmacology

The formulation provides a subject for investigating how compounds with overlapping and distinct receptor targets interact.

A central research question is whether two GHRH receptor agonists produce distinguishable effects when examined alongside a ghrelin receptor agonist.

2. Growth Hormone Regulation

Research into GHRH analogues and growth hormone secretagogues has contributed to understanding pituitary hormone secretion.

Studies of the individual compounds provide background information about their signalling pathways, but do not establish the response of this specific three-component formulation.

3. Visceral Adipose Tissue Research

Tesamorelin has been investigated in controlled human trials involving excess visceral abdominal fat associated with HIV-related lipodystrophy.

These findings demonstrate an established research application for Tesamorelin.

They do not establish that the triple combination produces equivalent or superior changes in visceral adipose tissue.

4. Hormonal Selectivity

Ipamorelin has been investigated for its comparatively selective growth hormone-releasing activity in preclinical models.

Research into combinations must separately consider whether additional compounds influence hormonal selectivity, endocrine feedback or receptor responses.

5. IGF-1 and Metabolic Signalling

Growth hormone influences insulin-like growth factor-1 production and participates in metabolic regulation.

Investigations involving growth hormone secretagogues contribute to understanding these upstream endocrine pathways.

However, increases in growth hormone or IGF-1 do not establish improvements in muscle development or metabolic health.

How This Combination Differs from Other Peptide Blends

Tesamorelin + CJC-1295 No DAC + Ipamorelin

Contains two GHRH analogues acting through the same receptor system and one ghrelin receptor agonist. Its distinctive research question concerns the interaction between overlapping and complementary signalling mechanisms.

Tesamorelin + Ipamorelin

Combines one GHRH analogue with one ghrelin receptor agonist, without the additional CJC-1295 No DAC component.

CJC-1295 No DAC + Ipamorelin

Combines a modified GHRH analogue with a comparatively selective growth hormone secretagogue.

Sermorelin + Ipamorelin

Pairs the biologically active 29-amino-acid GHRH fragment with Ipamorelin, providing a different GHRH analogue structure.

These formulations should be distinguished by their actual constituent compounds and receptor mechanisms rather than assuming that additional ingredients necessarily produce greater biological effects.

Product Specifications

• Product: Tesamorelin + CJC-1295 No DAC + Ipamorelin
• Tesamorelin quantity: 6mg
• CJC-1295 No DAC quantity: 3mg
• Ipamorelin quantity: 3mg
• Total peptide content: 12mg
• Format: 3ml pen
• Classification: Triple-peptide growth hormone research formulation
• Primary receptors: GHRHR and GHS-R1a
• Research focus: Pituitary signalling, receptor interactions and growth hormone regulation
• Additional research areas: IGF-1 signalling, endocrine selectivity and metabolic physiology
• Evidence status: Investigational combination without established clinical efficacy

Research Peptide Formulations from Coridion Sciences

Coridion Sciences maintains a catalogue of individual research peptides and combination formulations investigated across endocrine regulation, cellular signalling and metabolic physiology.

The Tesamorelin + CJC-1295 No DAC + Ipamorelin formulation brings together three compounds with distinct molecular structures and partially overlapping pharmacological mechanisms.

Research Use Only: This combination is intended exclusively for scientific and laboratory research. It is not approved for human consumption, medical treatment, weight-loss therapy, muscle-building or athletic performance enhancement. Clinical research involving an individual ingredient does not establish the safety or efficacy of this specific formulation.

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

Overlapping pathways

Both GHRH constituents act at the same receptor, so their effects are not mechanistically distinct.

Tesamorelin trial data

The most clinically documented GHRH analogue available for research.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.